A small clinical trial led by the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine has shown promising results by adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy for advanced lung cancer. The study published in Science highlighted the importance of reducing chronic inflammation while maintaining initial inflammatory responses for effective treatment. Using a JAK1 inhibitor, the trial achieved a high response rate of 67% and a median progression-free survival of nearly 24 months in patients with advanced non-small cell lung cancer. Future research will focus on larger trials and the role of JAK1 inhibition in patients with disease progression on immunotherapy.
Source link
JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer
